Compare Quest Diagnostics Inc (DGX) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs EPAM Systems Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while EPAM Systems Inc trades at $113.24 (market cap $5.87B). The key difference: Quest Diagnostics Inc is far larger — about 4.3× EPAM Systems Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and EPAM Systems Inc for 37 Days on average.
| DGX | EPAM | |
|---|---|---|
Market Cap | $25.48B | $5.87B |
Volume | 941,866 | 847,420 |
Sector | Health | Technology |
52-Week High | $247.45 | $221.40 |
52-Week Low | $173.49 | $76.04 |
Typical Hold Time | 56 Days | 37 Days |
Enterprise Value | $31.23B | $5.24B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
EPAM Systems trades at $113.24, up 4.54% today, reflecting strong momentum. The stock shows a bullish technical trend, trading near resistance at $115. Fundamentally, EPAM reported Q2 2026 EPS of $3.38, beating estimates, with revenue reaching $5.46B in 2025. Recent news highlights a partnership with Wiz for cloud security and activist investor Engine Capital urging share buybacks, signaling confidence in undervaluation.
The outlook is positive, supported by a consensus price target of $119 and strong analyst buy ratings (59.46%). However, risks include slower North American growth and AI disruption to legacy services. The stock presents a value opportunity with a P/E of 15.45, but investors should monitor execution on AI-native revenue growth and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
